Depressive Symptoms

2
Pipeline Programs
4
Companies
3
Clinical Trials
1 recruiting
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
2
Early DiscoveryClinical DevelopmentMarket

On Market (1)

Approved therapies currently available

U
RASAGILINE MESYLATEApproved
rasagiline
Unknown Company
oral2024

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Teva
TevaIsrael - Petach Tikva
1 program
1
RasagilinePhase 41 trial
Active Trials
NCT01055379Completed121Est. Jul 2012
Precision BioSciences
1 program
Common Elements ToolboxN/A1 trial
Active Trials
NCT04815681Withdrawn0Est. Dec 2022
Jerusalem Pharmaceuticals
Jerusalem PharmaceuticalsIsrael - Ramallah
1 program
GOLD-Cog+N/A1 trial
Active Trials
NCT06631781Recruiting42Est. Sep 2025

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
TevaRasagiline
Jerusalem PharmaceuticalsGOLD-Cog+
Precision BioSciencesCommon Elements Toolbox

Clinical Trials (3)

Total enrollment: 163 patients across 3 trials

NCT01055379TevaRasagiline

Rasagiline in Cognitive-impairment Related Depression: AzileCt in COgnitive-impairment Related DepressiOn

Start: Mar 2010Est. completion: Jul 2012121 patients
Phase 4Completed
NCT06631781Jerusalem PharmaceuticalsGOLD-Cog+

Cognitive Control Mechanisms in Older Adults

Start: Feb 2024Est. completion: Sep 202542 patients
N/ARecruiting
NCT04815681Precision BioSciencesCommon Elements Toolbox

Evaluating an Online Wellness Intervention for Greek Adolescents

Start: Mar 2021Est. completion: Dec 20220
N/AWithdrawn

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 163 patients
4 companies competing in this space